The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already
The stock of Norwegian contrast agent developer Nycomed rose on the Oslo stock exchange this month on rumors that the company was exploring closer ties with German pharmaceutical company Altana Industrie-Aktien und Anlagen. The companies are already jointly marketing an ulcer drug, and may be looking for ways to expand their partnership, according to AFX News.
Nycomed has been the subject of merger or acquisition rumors since its proposed merger with U.S. generic drug firm Ivax broke down in 1995 (SCAN 12/13/95). The company said at the time the deal fell apart that it would continue to pursue strategic partnerships. Nycomed executives declined to comment on the Altana rumors.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.
Stroke MRI Study Assesses Impact of Motion Artifacts Upon AI and Radiologist Lesion Detection
July 16th 2025Noting a 7.4 percent incidence of motion artifacts on brain MRI scans for suspected stroke patients, the authors of a new study found that motion artifacts can reduce radiologist and AI accuracy for detecting hemorrhagic lesions.
2 Commerce Drive
Cranbury, NJ 08512